Hemogenyx Pharmaceuticals PLC
HEMO
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
Higher gold prices boosted profit yet shares remain materially overvalued.
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.00 | 79.70 | 0.88% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,310.85 | 103.67 | 0.41% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 62,734.68 | 369.76 | 0.59% |
| NZX 50 Index | 13,876.23 | 14.30 | 0.10% |
| S&P 500 | 7,428.78 | 15.60 | 0.21% |
| S&P/ASX 200 | 8,947.80 | 85.60 | 0.97% |
| SSE Composite Index | 3,813.31 | 44.93 | -1.16% |